[A22-92] Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2022
Project no.:
A22-92
Commission:
Commission awarded on 29.08.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-91 | Upadacitinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-116 | Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-16 | Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-15 | Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-08 | Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-38 | Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |